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A B S T R A C T
Purpose: Epilepsy is the third most common chronic brain disorder and is characterized by an enduring
predisposition for seizures. Recently, a growing body of evidence has suggested that microRNA-146a
(miR-146a) is upregulated in the brains of epilepsy patients and of mouse models; furthermore, miR-
146a may be involved in the development and progression of seizures through the regulation of
inﬂammation and immune responses. In this report, we performed a case–control study to analyze the
relationship between the two potentially functional single nucleotide polymorphisms (SNPs) of the miR-
146a gene (rs2910464 and rs57095329) and the risk of epilepsy in a Chinese population comprising
249 cases and 249 healthy controls.
Method: Our study comprised 249 epilepsy patients and 249 healthy controls in two regions of China.
The DNA was genotyped using the ABI PRISM SNapShot method. The statistical analysis was estimated
using the chi-square test or Fisher’s exact test.
Results: Our results indicated a signiﬁcant association between the rs57095329 SNP of the miR-146a
gene and the risk of drug resistant epilepsy (DRE) (genotypes, p = 0.0258 and alleles, p = 0.0108).
Moreover, the rs57095329 A allele was found to be associated with a reduced risk of seizures frequency
in DRE patients (all p < 0.001). However, the rs2910164 variant was not associated with epilepsy.
Conclusion: Our data indicate that the rs57095329 polymorphism in the promoter region of miR-146a is
involved in the genetic susceptibility to DRE and the seizures frequency.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is a common, serious neurological disorder character-
ized by recurring unprovoked seizures that result from the
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unclear, increasing evidence shows that the persistent upregula-
tion of inﬂammatory gene expression contributes to the etio-
pathogenesis of epilepsy [2,3]. Additionally, inﬂammatory
mediators such as interleukin (IL)-1b, Toll-like receptors (TLRs),
and other factors are involved in the development of epilepsy in
experimental animal models and in patients [4,5].
MicroRNAs (miRNAs) are a family of small, endogenous
noncoding RNAs that post-transcriptionally regulate target gene
expression to control most aspects of biological processes,
including innate and adaptive immune responses [6–8]. Abnormal
miRNA expression has also been observed in different diseases
associated with inﬂammatory and immune processes [9–11]. One
miRNA that attracted our attention was miRNA-146a (miR-146a),served.
Table 1
Clinical and demographic data of epileptic patients.
Characteristics Epilepsy
patients
(N = 249)
TLE patients
(N = 174)
Non-TLE
patients
(N = 75)
Controls
(N = 249)
Age (mean
years  SD)
26.5  15.2 26.33  14.29 27.07  16.79 50.1  16.7
Gender (male/
female)
137/112 95/79 42/33 155/94
Age at epilepsy
onset (mean
years  SD)
19.42  14.38 19.68  13.31 18.87  16.55 –
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signaling pathway and of proinﬂammatory cytokines such as IL-1b
and TNF-a [12–14]. Recently, increasing evidence has shown that
miR-146a is upregulated in epilepsy mouse models and epilepsy
patients [15–18], suggesting that miR-146a may operate as an
important epigenetic regulator involved in the pathogenesis of
epilepsy.
Single nucleotide polymorphisms (SNPs) could inﬂuence the
function or the expression of genes and be associated with the risk
of disease. Two SNPs in the miR-146a gene, rs2910164 and
rs57095329, have functional importance: they modify the
expression level of mature miR-146a [19,20] and are associated
with many inﬂammation-associated diseases such as systemic
lupus erythematosus [19], Behc¸et’s disease [20] ulcerative colitis
[21], sepsis [22] and asthma [23]. To the best of our knowledge, no
studies have examined the association between the rs57095329
SNP and epilepsy, and only one study on the association between
one SNP (rs2910164) and the risk of temporal lobe epilepsy (TLE)
has been performed in a primarily Caucasian population
[24]. Until now, no similar studies have been performed in Asian
populations. In the present study, we conducted a case–control
study to determine the association between these two functional
SNPs of miR-146a (rs2910164 G>C and rs57095329 A>G) and
epilepsy in an ethnically homogeneous Chinese population.
Moreover, the potential associations between the miR-146a
polymorphisms and clinical variables such as TLE/no-TLE, drug-
responsiveness/resistance and seizure frequency were also
examined.
2. Materials and methods
2.1. Clinical data of epilepsy patients and healthy controls
Our study comprised 249 epilepsy patients (female 112; male
137; mean age: 26.5  15.2 years) and 249 healthy controls (female
94; male 155; mean age: 50.1  16.7 years). The epilepsy patients
were recruited from two regions of China: the Department of
Neurology of the Afﬁliated Hospital of Guangdong Medical College of
southern China (134 patients and 137 controls) and the Department
of Neurology of the ﬁrst Afﬁliated Hospital of Harbin Medical
University of northern China (115 patients and 112 controls). All of
the patients were diagnosed and classiﬁed by experienced neurol-
ogists following the criteria of the International League Against
Epilepsy [25]. Information such as the clinical history, electroen-
cephalography (EEG) and magnetic resonance imaging (MRI) data
was recorded for all patients. Patients and healthy controls with
mental retardation were excluded as well as all of the healthy control
subjects who had a history of seizures. The study was conducted in
accordance with the Declaration of Helsinki, and written informed
consent was obtained from all of the enrolled participants. This study
was approved by the Ethics Committees of both the Afﬁliated Hospital
of Guangdong Medical College and the ﬁrst Afﬁliated Hospital of
Harbin Medical University.
Patients were divided into two groups, according to treatment,
as drug responsive and drug resistant. Drug responsiveness was
determined from clinical records. A drug response was deﬁned as
freedom from seizures or a 50% or greater reduction in the seizure
frequency for at least one year during treatment with antiepileptic
drugs (AEDs). Drug resistance was deﬁned as no change or less a
than 50% reduction in the seizure frequency for at least one year
with two or more appropriate AEDs at maximally tolerated
therapeutic doses. Patients who underwent epilepsy surgery for
refractory epilepsy were classiﬁed as having drug-resistant
epilepsy, regardless of their postoperative seizure control status.
Moreover, the seizure frequencies of drug-resistant epilepsy (DRE)
patients were followed up and recorded. Twenty-three patientswere excluded because their seizure frequency data with follow up
included less than 6 months or because the patients underwent
epilepsy surgery within the previous 6 months. Finally, a total of
52 patients were included in these statistics and were divided into
groups according to their seizure frequencies, as follows: less than
5 times/month, more than 5 times/month, more than 10 times/
month and more than 30 times/month.
2.2. Genotyping
A 2-mL venous blood sample was taken for DNA extraction and
genotyping. Genomic DNA was isolated from peripheral blood
samples using a blood Genomic DNA Extraction Kit (Tiangen,
China). DNA was genotyped using the ABI PRISM SNapShot method
(Applied Biosystems, Foster, CA). The PCR primers used for the
rs2910164 SNP were as follows: forward primer 5-GAACTGAATTC-
CATGGGTTG-3 and reverse primer 5-CACGATGACAGAGATATCCC-
3. The primers used for the rs57095329 SNP were as follows:
forward primer 5-TCATTGGGCAGCCGATAAAG-3 and reverse
primer 5-AGGAAGTTCTGGTCAGGCG-3. The assay conditions were
in accordance with manufacturer’s protocols. Fluorescence out-
puts were quantiﬁed in real time by using a 7500HT Fast Real Time
PCR System (Applied Biosystems, Carlsbad, CA). For quality control,
random duplicate samples (5%) were run for each sequence
analysis.
2.3. Statistical analysis
All analyses were performed using SPSS version 19.0 (IBM, NY,
USA). Genotype and allele frequencies distributions in the groups
were counted and estimated using the chi-square test or Fisher’s
exact test. Deviation of the genotype or allele frequency was
assessed using Hardy–Weinberg equilibrium (HWE). The odds
ratio (OR) and 95% conﬁdence interval (CI) were calculated to
assess the correlation between the miR146a genotype and
epilepsy. The data are presented as percentage frequencies or
the means  SD. Two-tailed p values <0.05 were considered to be
statistically signiﬁcant.
3. Results
3.1. Clinical characteristics
The demographic characteristics of our subjects are shown in
Table 1. In total, 249 epilepsy patients and 249 healthy controls,
who were matched with case subjects according to sex, ethnicity
and geographic location of origin, were recruited in our study.
Among the cases, 174 patients were classiﬁed as TLE, and
75 patients were classiﬁed as non-TLE. No signiﬁcant differences
in the age and sex distributions between TLE patients and non-TLE
patients were found. Additionally, the average seizure onset age
was 19.42  14.38 years, and no statistically signiﬁcant difference
Table 2
Distribution of miR146a gene polymorphisms between epilepsy patients and healthy controls.
RS2910164 All CC (%) CG (%) GG (%) p-Value C (%) G (%) p-Value OR (95% CI)
CASE 249 98 (39.4) 120 (48.2) 31 (12.4) 0.1500 316 (63.5) 182 (36.5) 0.3279 1.146 (0.8872–1.480)
TLE 174 66 (37.9) 85 (48.9) 23 (13.2) 0.2649 217 (62.4) 131 (37.6) 0.5666 1.093 (0.8250–1.449)
No-TLE 75 32 (42.7) 35 (46.7) 8 (10.7) 0.2823 99 (66.0) 51 (34.0) 0.2144 1.281 (0.8738–1.878)
Control 249 97 (39.0) 106 (42.6) 46 (18.5) – 300 (60.2) 198 (39.8) – –
RS57095329 All AA (%) GA (%) GG (%) p-Value A (%) G (%) p-Value OR (95% CI)
CASE 249 163 (65.5) 79 (31.7) 7 (2.8) 0.7539 405 (81.3) 93 (18.7) 0.5230 1.122 (0.8199–1.535)
TLE 174 110 (63.2) 59 (33.9) 5 (2.9) 0.9677 279 (80.2) 69 (19.8) 0.8620 1.042 (0.7399–1.466)
No-TLE 75 53 (70.7) 20 (26. 7) 2 (2.7) 0.4099 126 (84.0) 24 (16.0) 0.2413 1.352 (0.8302–2.203)
Control 249 155 (62.2) 86 (34.5) 8 (3.2) – 396 (79.5) 102 (20.5) – –
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and non-TLE subgroups.
3.2. Genotype and allele frequency distributions in epilepsy patients
and controls
All of the enrolled subjects were successfully genotyped for the
rs2910164 and rs57095329 SNPs, and the association between the
genotype and the risk of epilepsy was analyzed using the chi-
square test. The deviation from Hardy–Weinberg equilibrium for
the polymorphisms examined was not found in the distributions of
genotypes in the patients and controls (all p > 0.05, data not
shown). The genotype and allele frequencies of miR-146a
polymorphisms in the studies are shown in Table 2. For
rs2910164, neither the genotype nor the allele showed signiﬁcant
differences between the epilepsy patients and the controls
(genotypes p = 0.1500 and alleles p = 0.3279, respectively), and
no signiﬁcant difference was observed in the TLE group (genotypes
p = 0.2649 and alleles p = 0.5666) or no-TLE groups (genotypes
p = 0.2823 and alleles p = 0.2144) (Table 2). Similarly, we also did
not observe a signiﬁcant difference in the genotype or allele
frequencies between the patients and controls for the rs57095329
SNP (epilepsy patients: genotypes p = 0.7539 and alleles
p = 0.5230; TLE patients: genotypes p = 0.9677 and alleles
p = 0.8612; no-TLE patients: genotypes p = 0.4099 and alleles
p = 0.2413). Additionally, as shown in Table 3, there was no
statistically signiﬁcant difference in the mean age of onset of
epilepsy in patients with an miR-146a polymorphism (genotype
for rs2910164: p = 0.253; genotype for rs57095329: p = 0.196). We
further performed haplotype-based association analyses of
rs2910164 and rs57095329. However, no signiﬁcant associations
were observed between these haplotypes and epilepsy (Table 4).
3.3. Genotype and allele frequency distributions of miR-146a
polymorphisms between DRE patients and controls
The distribution of miR-146a genotypes was further analyzed
in DRE patients and healthy controls. As shown in Table 5,
the rs2910164 SNP showed no signiﬁcant association with DRE
patients. However, rs57095329 showed a signiﬁcant association
in the DRE group compared with the controls (genotypesTable 3
Distribution of miR146a gene polymorphisms of onset age in epilepsy patients.
rs2910164 CC GC GG p-Value
Onset age 20.89  14.88 18.73  14.36 17.24  13.03 0.2531
rs57095329 AA GA GG p-Value
Onset age 20.80  15.25 16.88  12.30 20.13  12.26 0.1968p = 0.0258 and alleles p = 0.0108), and the patients carrying the
miRNA-146a rs57095329 A allele had a lower risk of DRE,
indicating that the rs57095329 SNP could be a risk factor for DRE.
3.4. Genotype and allele frequency distributions of miR-146a
polymorphisms among DRE patients
We collected the DRE patients with relatively stable seizure
frequencies and with full clinical data with at least one year follow-
up. A total of 52 DRE samples with relatively stable seizure
frequency data were recruited for the association analysis between
miR-146a polymorphisms and the seizure frequency. Among the
52 DRE patients, 31 patients had a seizure frequency of less than
5 times/month, 21 patients had a seizure frequency of more than
5 times/month, 16 patients had the seizure frequency of more than
10 times/month, and 7 patients had a seizure frequency of more
than 30 times/month (Table 6). We analyzed the genotype and
allele frequency distributions among DRE patients, and the results
are shown in Fig. 1. The rs2910164 polymorphism showed no
signiﬁcant association with the seizure frequency of the DRE
patients. However, the rs57095329 A allele was observed with a
trend of reducing the seizure frequency in DRE patients (all
p < 0.001), indicating that rs57095329 in the promoter region of
miR-146a was a risk factor for the seizure frequency of DRE
patients.
4. Discussion
Despite extensive research, the mechanisms underlying the
cause and progression of epilepsy remain unclear. In recent years,
increasing evidence has supported the hypothesis that inﬂamma-
tory processes within the epileptic brain might constitute a
common and crucial mechanism in the pathology of seizures
[26,27]. In the brain tissue of patients with DRE, several pro-
inﬂammatory cytokines have been detected [28,29], and in animal
models, the inﬂammatory mechanisms are also intimately
connected with the generation of seizure onset [30]. Importantly,
although controversial, several pieces of clinical evidence indicat-
ed that steroids and other anti-inﬂammatory treatments have
anticonvulsant properties in DRE patients [31,32], supporting the
view that the effects on neuroinﬂammation may inﬂuence theTable 4
The haplotype of miR146a polymorphisms between cases and controls.
rs2910164–
rs57095329
Case Control OR (95% CI) p-Value
CA 313 306 1 –
AG 86 94 0.894 (0.6420–1.247) 0.5100
GG 99 98 0.988 (0.7166–1.361) 0.9393
Table 5
Distribution of miR146a gene polymorphisms between DRE patients and controls.
rs2910164 CC (%) GC (%) GG (%) p-Value C (%) G (%) p-Value OR (95% CI)
Drug-resistant 31 (41.3) 33 (44.0) 11 (14.7) 0.6501 95 (63.3) 55 (36.7) 0.5059 1.1400 (0.7815–1.663)
Control 97 (40.0) 106 (42.6) 46 (18.5) – 300 (60.2) 198 (39.8) – –
rs57095329 AA (%) GA (%) GG (%) p-Value A (%) G (%) p-Value OR (95% CI)
Drug-resistant 34 (45.3) 36 (48.0) 5 (6.7) 0.0258 104 (69.3) 46 (30.7) 0.0108 0.5823 (0.3866–0.8773)
Control 155 (62.2) 86 (34.5) 8 (3.2) – 396 (79.5) 102 (20.5) – –
Table 6
Distribution of the seizure frequency in DRE patients.
Seizure frequency <5 times/month (N = 31) >5 times/month (N = 21) >10 times/month (N = 16) >30 times/month (N = 7)
rs2910164
CC 11 6 5 2
GC 15 12 10 5
GG 5 3 1 0
p-Value 0.8206 0.5333 0.4097
C allele 37 24 20 9
G allele 25 18 12 5
p-Value – 0.8409 0.8272 1
OR (95% CI) – 0.9009 (0.4070–1.994) 1.126 (0.4683–2.708) 1.216 (0.3643–4.060)
rs57095329
AA 24 10 7 2
GA 7 5 5 2
GG 0 6 4 3
p-Value 0.0051 0.0072 0.0005
A allele 55 25 19 6
G allele 7 17 13 8
p-Value – 0.0008 0.0026 0.0006
OR (95% CI) – 0.1872 (0.06890–0.5085) 0.1860 (0.06465–0.5352) 0.0955 (0.02552–0.3570)
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as a powerful innate immune- and pro-inﬂammatory-related
regulator in immune and inﬂammatory responses. MiR-146a has
been reported to be abnormally upregulated in several diseases
[33–35]. Recently, miRNA expression proﬁling assays of samples
under epilepsy conditions showed that miR-146a was signiﬁcantly
upregulated in the hippocampus both of a TLE rat model and of
epilepsy patients [15,16], and miR-146a also interacts with IL-1b
levels at different stages of epilepsy [14]. These ﬁndings inspired us
to examine the relationship between miR-146a and epilepsy.
In this case–control study, two functional SNPs in miR-146a
(rs2910164 and rs57095329) were selected to evaluate the
association between miR-146a polymorphisms and the risk of
epilepsy. The rs2910164 G/C polymorphism, which is located in
the stem region of precursor-miR146a and could disturb theFig. 1. Distribution of different seizures frequency in DRE patexpression of mature miR-146a through mismatching with the
stem structure, has been associated with several diseases
[21,36,37]. The rs57095329 polymorphism, which is located in
the miR-146a promoter, was recently found to inﬂuence mature
miR-146a levels by altering the binding afﬁnity of miR-146a for V-
Ets oncogene homologue 1 (Ets-1), thereby possibly contribute to
disease susceptibility [19]. Our previous study also conﬁrmed that
both of the 2 functional SNPs of miR-146a could inﬂuence the
expression levels of miR-146a in vitro [11]. However, in the
present study, only rs57095329 was associated with DRE
susceptibility. Why these two functional SNPs of miR-146a, which
can both inﬂuence miR-146a expression, show different correla-
tions with epilepsy in our association study remains unknown.
Because epilepsy is a complex disease that is associated with
multiple genetic and environmental factors, we inferred that theients with rs2910164 and rs57095329 allele of miR146a.
L. Cui et al. / Seizure 27 (2015) 60–6564functional rs2910164 SNP may have a limited capacity to alter the
susceptibility to epilepsy because it could only disturb miR-146a
expression by inﬂuencing the stem structure of precursor miR-
146a. Nevertheless, rs57095329 is located in the promoter region
of miR-146a. Thus, the effect of this SNP on the miR-146a
expression level relies mainly on Ets-1. Notably, Ets-1 is widely
expressed in the cortex and hippocampus and is upregulated in
Alzheimer’s disease, in which the inﬂammatory response is one of
the important pathological features [38], suggesting that
rs57095329 may have a potential function on the miR-146a
expression due to the high level of Ets-1 in the brain when
inﬂammation occurs such as in epilepsy. However, the effects of
rs57095329 and rs2910164 on miR-146a expression in the
epileptic brain require further study.
Another novel ﬁnding was that our statistical data showed a
connection between the rs57095329 A allele and the reduced
seizure frequency. Recently, increasing evidence suggested that
miR-146a may play a more important role before the onset of
seizures. E. Aronica and coworkers observed a prominent
upregulation of miR-146a in a mouse model at 1 week after
status epilepticus; furthermore, this upregulation persisted into
the chronic phase [15]. This ﬁnding was supported by another
study, which conﬁrmed that miR-146a expression was highest
in the latent stage and lowest in the acute stage in an MTLE rat
model; during the latent stage of seizures, a state of chronic
inﬂammation was also observed in epileptic patients [16]. More-
over, miR-146a is a potential powerful regulator and acts as a
regulating mechanism to prevent an excessive inﬂammatory
response [12,39–41]. Thus, we infer that miR-146a may serve as
a negative regulator of chronic inﬂammation in the latent stage
in epilepsy patients. Additionally, the rs57095329 A allele may
weaken the chronic inﬂammation in the latent stage of epilepsy
via increased miR-146a expression, thereby potentially reducing
the seizure frequency. DRE patients were chosen for this
analysis based on the following considerations: ﬁrst, obtaining
accurate data regarding seizure frequencies among epilepsy
patients who have not used AEDs in several months is difﬁcult,
and the drug-responsive patients who utilized AEDs in our study
lacked stable seizure frequencies; second, in contrast, the DRE
patients had a relatively homogeneous background and stable
seizure frequencies during the drug treatment. Thus, our results
do not exclude the possibility that this polymorphism may be
associated with the seizure frequency of the other subtypes of
epilepsy patients. However, because epilepsy is a multifactorial
disorder in which genetic susceptibility and environmental
factors may both be implicated, larger samples of epilepsy
patients, more clinical data and further study of the molecular
mechanism underlying this association are needed to conﬁrm
this association.
Our study has some potential limitations. Although we
recruited from two regions in China, the sample sizes of the case
and control groups in this study were still not large enough.
Moreover, the data regarding the seizure frequency of the DRE
patients were mainly collected by questionnaires and by continu-
ously recording clinical observations; thus, we cannot exclude the
existence of bias from the physician. Moreover, although associa-
tions between the miR-146a polymorphisms and DRE were
observed, the molecular mechanism of these associations is not
reﬂected in this case–control study. Our future studies will focus
on exploring the mechanisms underlying the connection between
miR-146a and epilepsy.
In summary, our study identiﬁed for the ﬁrst time a signiﬁcant
association between the rs57095329 polymorphism in the
promoter of miR-146a and the risk of DRE. The rs57095329 A
allele was associated with a reduced seizure frequency in DRE
patients.Conﬂict of interest
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